Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition?

About: CRISPR Therapeutics AG (CRSP), Includes: GILD, VRTX
by: BioSci Capital Partners
This article is exclusive for subscribers.

Gilead Sciences recently disclosed that the company is in discussion to potentially acquire a gene-editing company.

Bill Lundberg, M.D., recently stepped down as chief scientific officer to serve as senior advisor (and is replaced by Dr. Tony Ho).

Dr. Ho is the cream of the crops executive to lead this highly exciting waves of the potential breakthrough of our lifetime.

"It is not necessary to do extraordinary things to get extraordinary results." - The Oracle of Omaha (Warren Buffett)

Back on Feb. 8, 2018, we featured Crispr Therapeutics (NASDAQ:CRSP), a leading gene-editing innovator